Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study  by Wilson, Caroline et al.
Contents lists available at ScienceDirect
Journal of Bone Oncology
journal homepage: www.elsevier.com/locate/jbo
Research paper
Reproductive hormone analyses and eﬀects of adjuvant zoledronic acid in
early breast cancer – An AZURE (BIG 01/04) sub-study
Caroline Wilsona,⁎, Samantha Hinsleyb, Helen Marshallb, David Cameronc, Richard Belld,
David Dodwelle, Robert E. Colemana
a Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheﬃeld, Sheﬃeld, UK
b Leeds Cancer Clinical Trials Unit, University of Leeds, Leeds, UK
c Edinburgh Cancer Research Center, ECRC and Western General Hospital, University of Edinburgh, UK
d Deakin University, Geelong, Victoria 3220, Australia
e St James University Hospital, University of Leeds, UK







A B S T R A C T
Purpose: Adjuvant bisphosphonates have been shown to improve disease outcomes in early breast cancer in
women who are postmenopausal at the start of treatment. We explored the inﬂuence of pretreatment serum
levels of reproductive hormones in the hypothalamic-pituitary-gonadal (HPG) axis from a subset of patients
included in the AZURE trial to investigate their impact on disease recurrence and whether reproductive
hormone measurements are of value in selecting patients for treatment with adjuvant zoledronic acid.
Patients and methods; The AZURE trial is an academic, multi-centre, international phase III trial that
randomised patients to standard adjuvant therapy (chemotherapy and/or endocrine therapy) ± intravenous
zoledronic acid, 4 mg for 5 years. Serum from 865 patients taken at randomisation was stored at −80 °C prior to
central batch analysis for inhibin A, oestradiol and follicle stimulating hormone (FSH). We assessed the clinical
value of pretreatment hormone levels for predicting invasive disease free survival (IDFS), skeletal recurrence
and distant recurrence and response to treatment with zoledronic acid.
Results: Oestradiol in the postmenopausal range ( < 50 pmol/l) was associated with a signiﬁcantly shorter IDFS
(HR 1.36 95%CI: 1.05–1.78 p=0.022), predominantly due to distant recurrence (HR 1.33 95%CI: 0.98–1.81
p=0.065), compared to oestradiol ≥50pmol/l. In contrast, FSH in the postmenopausal range ( > 26 IU/l) was
associated with a longer time to bone as ﬁrst recurrence (HR 0.66 95%CI: 0.41–1.04 p=0.072) compared to an
FSH ≤26 IU/l. When all 3 hormone levels were within the assay speciﬁed postmenopausal range, a trend to
improved IDFS was seen with addition of zoledronic acid in biochemically postmenopausal women only
(postmenopausal HR=0.81; 95%CI: 0.54–1.22, non-postmenopausal HR=0.99; 95%CI: 0.69–1.39) with risk
reductions that mirrored the results of the main AZURE study, although the interaction between menopausal
status and treatment eﬀect was not statistically signiﬁcant (p=0.47).
Conclusion: Oestradiol and FSH may inﬂuence the pattern of disease recurrence with postmenopausal levels
possibly creating a less conducive environment for the formation of bone metastases, therefore disseminated
tumour cells could seek alternative niches outside of bone. Biochemical evaluation of a panel of reproductive
hormones may be helpful to assist selection of patients for adjuvant zoledronic acid when menopausal status is
unknown.
1. Introduction
Bone is a common site for breast cancer metastases [1] and spread
of tumour cells to bone may be an early event in the natural history of
the disease, occurring before the primary tumour is clinically detected.
These disseminated tumour cells (DTCs) have stem cell like properties
[2] with the capacity to form new tumour colonies in bone. The
presence of DTCs at diagnosis is an independent poor prognostic factor
and 50% of patients with detectable DTCs will relapse within 10 years
[3]. This relapse may be within the bone or at extra skeletal sites and
can occur at any time over at least 20 years after the primary tumour
diagnosis. The propensity of breast cancer for late relapse suggests that
these DTCs may be held in a state of dormancy within the bone
microenvironment with increasing evidence suggesting that dormant
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cells can reside in hematopoietic stem cell (HSC) and osteoblastic
niches within the bone [4]. Within these niches the tumour cells are
under the same local bone environmental factors that inﬂuence HSCs
and may revert to a non-dividing phenotype showing cell cycle arrest
[5] that confers resistance to adjuvant therapy [6]. The bone marrow
microenvironment is therefore key in determining the fate of these
DTCs, and can be modiﬁed by both bone targeted therapy such as
bisphosphonates [7–9] and also host factors including the levels of
reproductive hormones within the HPG axis such as oestradiol, FSH
and inhibin A (an ovarian secreted hormone that inhibits FSH) [10–
12].
Menopausal status has been shown to aﬀect breast cancer recur-
rence (higher incidence and prevalence in bone in premenopausal
women) [3,13] indicating that hormones within the HPG axis may
inﬂuence both the homing of breast cancer cells to bone and sub-
sequent progression to established bone metastases.
Clinical trials of the bone targeting agents, bisphosphonates, have
been conducted over the past 20 years with the aim of preventing the
formation of bone metastases. Bisphosphonates are analogues of
pyrophosphate that bind avidly to bone and are taken up by osteoclasts
in which they induce apoptosis [14,15]. When combined with che-
motherapy they appear to have direct anti-tumour eﬀects in vivo [16].
Bisphosphonates such as zoledronic acid have been shown to aﬀect
cells within the bone microenvironment and inﬂuence the ability of
tumour cells to both home to bone niches and establish as metastases.
For example, zoledronic acid can reduce the proliferation and migra-
tion of HSC's, and thereby decrease their ability to attract tumour cells
[17]. In clinical studies, zoledronic acid decreased the number of DTCs
in bone marrow aspirates from breast cancer patients [18–20]
suggesting either the DTCs had been killed, moved to another site in
the body or had entered into a state of dormancy with altered surface
protein expression that could not be detected by the tumour cell
extraction techniques utilized in these studies.
The interplay between bisphosphonates, menopausal status and
breast cancer recurrence was demonstrated in large prospective
adjuvant phase III trials of zoledronic acid with improvements in
disease outcomes with zoledronic acid demonstrated only in women
who were either naturally in established menopause [7,8] or had
undergone a chemically induced menopause [9]. A meta-analysis of
individual patient data from 18,766 women treated with adjuvant
bisphosphonates conﬁrmed that women who were postmenopausal
(deﬁned clinically) at the initiation of adjuvant bisphosphonates had
reduced recurrence rates at all distant sites (RR 0.82, 0.74–0.92;
2p=0.0003), in bone speciﬁcally (0.72, 0.60–0.86; 2p=0.0002) and
Table 1
Baseline characteristics for the 806 patients included in the serum population analysis (patients receiving HRT, tibolone or endocrine therapy at baseline are excluded) in addition to the
overall AZURE population.
Overall study Serum population
Standard treatment alone Standard treatment+Zoledronic acid
Number Percent Number Percent Number Percent
Lymph nodes
0 62 1.8 7 1.8 9 2.2
One–three nodes involved 2075 61.8 246 61.5 240 59.1
= > four nodes involved 1211 36 147 36.8 155 38.2
Unknown involvement 11 0.3 0 0.0 2 0.5
T stage
T1 1065 31.7 116 29.0 136 33.5
T2 1717 51.1 212 53.0 188 46.3
T3 456 13.6 56 14.0 69 17.0
T4 117 3.5 16 4.0 13 3.2
ER status
ER positive 2634 78.4 304 76.0 316 77.8
ER negative 705 21 95 23.8 88 21.7
ER unknown 20 0.6 1 0.3 2 0.5
Clinical menopausal status
Pre-menopausal 1503 44.7 195 48.8 193 47.5
Less than/equal to 5 years post 490 14.6 57 14.3 58 14.3
More than 5 years post 1041 31 119 29.8 118 29.1
Menstrual status unknown 324 9.6 29 7.3 37 9.1
Total 3359 100.0 400 100.0 406 100.0
Table 2
Clinical and biochemical menopausal categorisation of patients in the serum population (patients receiving HRT, tibolone or endocrine therapy at baseline are excluded).
Menopausal status (clinical categorisation) Total
Pre-menopausal Less than or equal to 5 years
since menopause








Non post-menopausal 357 92.0 66 57.4 40 16.9 42 63.6 505 62.7
Post-menopausal 31 8.0 49 42.6 197 83.1 24 36.4 301 37.3
Total 388 100.0 115 100.0 237 100.0 66 100.0 806 100.0
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improved overall breast cancer mortality (0.82, 0.73–0.93; 2p=0.002)
[21].
In this study, we present results from the analyses of the serum
concentrations of follicle stimulating hormone (FSH), oestradiol and
inhibin A from a subset of early breast cancer patients included in the
AZURE (BIG 01/04) trial taken prior to the commencement of
randomised study treatment (zoledronic acid or control), and assess
the potential clinical value of these hormones for predicting disease
outcomes and response to bone targeted therapy.
2. Patients and methods
2.1. Study population
The AZURE trial was an academic, multi-centre, international
phase III trial that recruited 3360 women with node positive Stage
II/III breast cancer between 1.9.03 and 16.2.06. Patients were
randomized 1:1 using a computer generated system which included
the following minimization criteria; number of involved lymph nodes,
clinical tumour stage, oestrogen receptor status, clinical menopausal
status (premenopausal, ≤5 years postmenopausal, > 5 years postme-
nopausal, unknown), type and timing of systemic therapy, study centre
and statin use. Patients received standard adjuvant therapy (che-
motherapy and/or endocrine therapy) ± intravenous zoledronic acid,
4 mg for 5 years, initially q3-4 wk and then with increasing intervals
between doses [8]. Eligibility criteria for the AZURE trial have been
reported previously [8] and included patients aged > 18 years with
histologically conﬁrmed breast cancer with N1 disease or a T3-4
primary tumour. Patients were excluded if there was clinical or imaging
evidence of metastases or if the primary tumour could not be fully
surgically excised.
2.2. Patient evaluation
The primary endpoint of AZURE was disease free survival (DFS)
with pre-speciﬁed subgroup analyses planned for the minimization
criteria. Secondary endpoints included invasive disease free survival
(IDFS, excluding in situ recurrence8), overall survival (OS), bone as
ﬁrst recurrence and distant recurrence. 966 DFS events were observed
in the AZURE trial at the time of the last data-lock on April 30th, 2013
after a median follow up of approximately 84 (IQR 71–92) months.
Baseline serum samples from 865 patients were collected following
informed consent and prior to randomized treatment allocation with
either standard adjuvant therapy alone (control) or standard adjuvant
therapy plus zoledronic acid. Serum was stored at −20 °C or below at
recruiting sites prior to shipment frozen for central storage at −80 °C in
Sheﬃeld prior to central batch analysis. 59 patients were excluded due
to recent or current medication (hormone replacement therapy,
tibilone and tamoxifen) at the time of serum collection that may alter
levels of reproductive hormones.
Inhibin A analysis was performed on an automated ACCESS
chemiluminescence immunoassay system from Beckman Coulter Ref
A36097. Oestradiol and FSH analysis were performed on an automated
Roche 602 Elecsys electrochemiluminescence immunoassay. All assays
were used according to manufacturer's instructions and without
modiﬁcations to the methods. FSH levels were standardized to the
second International Reference Preparation 78/549. Lower limit of
detection for the assays were as follows; inhibin A < 1 pg/ml,
oestradiol 18.4pmol/l, FSH 0.1 IU/L. Internal quality control materials
were run every 24 h covering 3 levels of analyte (low, medium and
high), and reference ranges for pre- and postmenopausal women were
assay speciﬁc, determined by the manufacturer and validated in-house.
2.3. Statistical methods
Assay speciﬁc reference ranges were used to compare postmeno-
pausal and non-postmenopausal levels of hormones. The following
hormone levels fulﬁlled the deﬁnition of postmenopausal; FSH >
26 IU/l, oestradiol < 50 pmol/l, Inhibin A < 3.6 pg/ml. If any one of
these criteria were not fulﬁlled the patient was classiﬁed as non-
postmenopausal. IDFS was selected as the primary endpoint for
analysis. Additional endpoints assessed were skeletal recurrence and
distant recurrence. Kaplan-Meier survival curves were used to assess
rates of IDFS and cumulative incidence function curves were used to
assess rates of bone as ﬁrst recurrence and distant recurrence.
Diﬀerences in outcomes between groups were assessed using the log-
rank test and Cox's proportional hazards model and analyses of
diﬀerent hormone levels were adjusted for the factors found to be
signiﬁcant for the relevant endpoint in the main AZURE analyses (i.e.
analyses were adjusted for randomised treatment only if this was
signiﬁcant in the relevant main AZURE analysis). IDFS was adjusted
for tumour stage, ER status, lymph node involvement and use of neo-
adjuvant therapy rather than postoperative adjuvant therapy as per the
main AZURE analyses. Time to bone as ﬁrst recurrence was adjusted
for randomised treatment allocation, tumour stage and lymph node
involvement (not adjusted for ER as this was not signiﬁcant in the main
AZURE analysis). Time to ﬁrst distant recurrence analyses were
adjusted for tumour stage, ER status and lymph node status. When
assessing the interaction of individual hormone levels with treatment,
analyses were adjusted for randomised treatment allocation. P-values
were considered signiﬁcant at α < 0.05 with no adjustments made for
multiple testing as all ﬁndings are considered exploratory and hypoth-
esis generating. All analyses were performed with the use of SAS
software version 9.2 or 9.4.
3. Results
3.1. Patient characteristics
806 patients were eligible for inclusion in the reproductive hor-
mone analysis, and the disease outcomes used for this analysis were
IDFS (230 events), bone as ﬁrst recurrence (74 events) and distant
recurrence (174 events). Patient disease characteristics and menopau-
sal status of these 806 patients and the overall AZURE study popula-
tion are presented in Table 1. The characteristics of the subgroup
available for analysis were very similar to the overall AZURE popula-
tion. Thirty-one (8%) clinically premenopausal women were biochemi-
Table 3
IDFS outcomes, skeletal and distant recurrence for non-postmenopausal vs postmeno-
pausal levels of hormones.
Analysis HR (95%CI) P value
Oestradiol pmol/l
( < 50Φ vs ≥50)
IDFS 1.36 (1.05–1.78) 0.022
Skeletal recurrence 1.15 (0.71–1.83) 0.575
Distant recurrence 1.33 (0.98–1.81) 0.065
Inhibin pg/ml
( < 3.6Φ vs. ≥3.6)
IDFS 1.17 (0.9–1.53) 0.239
Skeletal recurrence 0.99 (0.63–1.57) 0.972
Distant recurrence 1.1 (0.81–1.49) 0.534
FSH IU/l
( > 26Φ vs ≤26)
IDFS 0.96 (0.74–1.26) 0.779
Skeletal recurrence 0.66 (0.41–1.04) 0.072
Distant recurrence 0.86 (0.63–1.16) 0.331
If HR > 1 then the risk of experiencing an event is greater in the reference group (Φ).
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cally classiﬁed as postmenopausal, of these 1 woman was aged 29 and
the remainder were aged ≥44 years. Forty (16.9%) clinically > 5 years
postmenopausal’ women were biochemically classiﬁed as non-postme-
nopausal (see Table 2). Of these 43 women, the biochemical classiﬁca-
tion of postmenopausal status was not attained in the majority due to
an oestradiol level still within the premenopausal range (70%).
3.2. Baseline oestradiol and FSH may inﬂuence disease recurrence
patterns
Non-postmenopausal vs postmenopausal levels of FSH, oestradiol
and inhibin A were compared for IDFS, bone as ﬁrst recurrence and
distant recurrence (see Table 3).
An oestradiol of < 50 pmol/l (postmenopausal range) was asso-
ciated with a signiﬁcantly shorter IDFS compared to an oestradiol of
≥50 pmol/l (HR=1.36; 95% CI 1.05–1.78 p=0.022) (see Fig. 1A). Time
to bone as ﬁrst recurrence was not signiﬁcantly diﬀerent between
postmenopausal and non-postmenopausal levels of oestradiol
(HR=1.15; 95% CI 0.71–1.83, p=0.575), however, an oestradiol of <
50 pmol/l was associated with a shorter time to distant recurrence
compared to an oestradiol ≥50 pmol/l (HR=1.33; 95% CI 0.98–1.81
p=0.065).
IDFS did not signiﬁcantly diﬀer between postmenopausal and non-
postmenopausal levels of FSH (HR=0.96; 95% CI 0.74–1.26,
p=0.7794); however, an FSH of > 26 IU/l (postmenopausal range)
was associated with a longer time to bone as ﬁrst recurrence compared
to an FSH ≤26 IU/l (HR=0.66 95% CI: 0.41–1.04 p=0.072) although
this was not statistically signiﬁcant at the 5% level (Fig. 1B).
No signiﬁcant diﬀerences in disease outcomes were seen between
postmenopausal and non-postmenopausal levels of inhibin A.
The eﬀect of age on recurrence, independent of treatment, was
evaluated in the control group of patients (no zoledronic acid) in the
overall AZURE population (n=1678). Comparison of recurrence rates
by age categories showed age to be a signiﬁcant prognostic factor with a
Fig. 1. A Baseline oestradiol as a prognostic marker for IDFS. Time to invasive disease recurrence or death (any cause) in patients with serum oestradiol < 50 pmol/l (red line) vs
≥50 pmol/l (blue line). Data represents adjusted hazard ratios (HR) and 95% conﬁdence interval (CI) B Baseline FSH as a prognostic marker for time to bone as ﬁrst recurrence. Time to
bone as ﬁrst recurrence in patients with serum FSH ≤26 IU/l (blue line) vs > 26 IU/l (red line). Data represents adjusted hazard ratios (HR) and 95% conﬁdence interval (CI).
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Fig. 2. Overall invasive disease free survival according to age. Data represents adjusted hazard ratios (HR) and 95% conﬁdence interval (CI).
Table 4
IDFS outcomes, skeletal and distant recurrence according to age.
Analysis according to age category HR (95%CI) P value
IDFS
40–49 vs < 40 0.87 (0.66–1.15) 0.0025
50–59 vs < 40 0.81 (0.61–1.07)
60–69 vs < 40 1.22 (0.91–1.64)
≥70 vs < 40 1.44 (0.92–2.26)
Skeletal recurrence
40–49 vs < 40 0.81 (0.52–1.25) 0.12
50–59 vs < 40 0.75 (0.48–1.17)
60–69 vs < 40 0.82 (0.5–1.35)
≥70 vs < 40 1.82 (0.92–3.58)
Distant recurrence
40–49 vs < 40 0.86 (0.58–1.29) 0.068
50–59 vs < 40 0.79 (0.53–1.19)
60–69 vs < 40 1.25 (0.82–1.91)
≥70 vs < 40 1.32 (0.71–2.47)
If HR< 1 then the risk of experiencing an event is greater in the reference group ( < 40).
Fig. 3. Invasive disease free survival (IDFS) outcomes in the main AZURE population
and the serum AZURE population. Data represents adjusted hazard ratios (HR) and 95%
conﬁdence interval (CI). Postmenopausal (PM) represents patients clinically > 5 years
PM in the main AZURE population or biochemically postmenopausal in the serum
population, and non-postmenopausal (non-PM) represents patients < 5 years PM,
premenopausal and unknown menopausal status in the main AZURE population or
biochemically non-postmenopausal in the serum population. The heterogeneity of
treatment eﬀect according to menopausal status was statistically signiﬁcant in the main
AZURE population (p=0.0300) but not in the serum AZURE population (p=0.4699).
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shorter IDFS in patients < 40 years and ≥60 years (p=0.0025) (see
Fig. 2). The recurrence sites in women < 40 years suggest they
experienced more skeletal recurrences as their ﬁrst recurrence than
any other age group (excluding women ≥70 years in whom there were
fewer events and thus wide conﬁdence intervals around the recurrence
risk estimates). Women ≥60 years experienced more distant recurrence
compared to women < 40 years which appears to be driven by
recurrence outside the bone (see Table 4).
3.3. Biochemically postmenopausal patients continue to experience
improved IDFS outcomes with zoledronic acid
The eﬀect of zoledronic acid on IDFS was compared in biochemi-
cally postmenopausal women and non-postmenopausal women using a
combined assessment of oestradiol, FSH and inhibin A (see Fig. 3). The
risk reduction for IDFS with the addition of zoledronic acid to standard
therapy in biochemically postmenopausal women (HR=0.81; 95% CI
0.54–1.22) was similar to that seen in the overall study (HR for women
> 5 years postmenopausal 0.77; 95% CI 0.63–0.96) although, probably
due to relatively small number of events, the upper 95% conﬁdence
interval overlaps unity. In biochemically non-postmenopausal women,
IDFS was unaﬀected by treatment allocation (HR=0.98; 95% CI 0.69–
1.39), mirroring the ﬁndings of the overall study (HR for women not >
5 years postmenopausal=1.03 95% CI 0.89–1.2). However, unlike in
the study as a whole and probably due to the limited number of events,
the interaction between menopausal status and treatment was not
statistically signiﬁcant (p=0.47). There was a trend towards a reduced
skeletal recurrence in biochemically pre- and postmenopausal patients
(postmenopausal HR 0.81; 95% CI 0.37–1.8, premenopausal HR 0.82;
95%CI 0.46–1.46) with additional beneﬁt in distant non skeletal
disease recurrence suggested in postmenopausal women only (HR
0.91; 95%CI 0.5–1.7). These ﬁndings were not statistically signiﬁcant
again perhaps due to a limited number of events. Further follow-up
with the addition of more events should help clarify these ﬁndings.
4. Discussion
These results suggest that women with postmenopausal levels of
oestradiol at diagnosis have a signiﬁcantly shorter IDFS, which may be
driven by recurrence outside the bones. This may be due to the eﬀect of
the hormones on bone cell function creating a microenvironment that
is either less attractive to DTCs or less conducive to their autonomous
growth into metastasis, and potentially inﬂuencing them to seek
alternative ‘metastatic niches’ outside of bone. The increased distant
recurrence rate in women with low oestradiol was probably linked to
selection of older women with more aggressive disease for the trial
rather than poorer disease outcomes per se in older women. The
suggested increase in skeletal recurrence in the under 40 s may infer
that FSH can inﬂuence bone recurrence as this age group would be
expected to have low FSH levels due to negative feedback on the
pituitary from high levels of cycling ovarian hormones. However, the
relatively small number of events limits our study and further data are
required to address this deﬁnitively.
Our ﬁndings are supported by clinical studies evaluating the
presence of DTCs from breast cancer in the bone marrow at diagnosis.
A large meta-analysis (n=4700) of the prevalence of bone marrow
DTCs demonstrated that premenopausal patients had a signiﬁcantly
higher prevalence compared to postmenopausal women (premenopau-
sal 32.7%, post menopausal 29.5% p=0.02) [3] and a retrospective
evaluation of recurrence patterns in 7064 women diagnosed with
breast cancer showed younger women were signiﬁcantly more likely
to develop bone metastases [13], suggesting premenopausal bone may
be a more attractive microenvironment for survival of tumour cells. In
addition, data on recurrence patterns of 6792 breast cancer patients
entered into trials conducted by the International Breast Cancer Study
Group showed that younger patients ( < 35 years) had signiﬁcantly
higher incidences of bone metastases occurring during the course of
their disease [22].
Improving disease outcomes by addition of zoledronic acid to
standard therapy was evaluated in the AZURE study [8] and the
ABCSG 12 study [23]. In these studies sub-group analyses showed that
the beneﬁcial eﬀects of zoledronic acid on disease outcomes were
driven by women in whom very low levels of HPG activity would be
expected > 5 years since menopause in AZURE (overall survival;
HR=0.75; 95%CI 0.59–0.96 p=0.02) and > 40 years and receiving
goserelin in ABCSG-12 (disease free survival; HR=0.58, 95% CI 0.40–
0.84). The beneﬁcial eﬀects of adjuvant bisphosphonates have been
conﬁrmed in a large meta-analysis of pre- and postmenopausal
patients treated in adjuvant bisphosphonates trials. For the meta-
analysis, patients were deﬁned clinically as pre- or postmenopausal. In
postmenopausal women there was a signiﬁcant reduction in breast
cancer recurrence, particularly in bone, and a clinically important
reduction in breast cancer mortality [21]. Biochemical analysis of
hormones was not performed in all of these trials and therefore its
utility in selecting patients for adjuvant bisphosphonates has not been
evaluated in a large patient cohort. Our results suggest that selection of
patients for adjuvant bisphosphonates where menopausal status is
unknown might be done using a biochemical analysis of inhibin A, FSH
and oestradiol to conﬁrm levels are within the postmenopausal range
for the assay used.
Pre-menopausal/younger bone is associated with relatively low
levels of osteoclast activity and thus alternative mechanisms may be
driving the homing to and establishment of DTCs in bone. This may
explain why bisphosphonates, as osteoclast targeting drugs, are not
aﬀecting disease outcomes in premenopausal women and there re-
mains a need to identify bone-targeting drugs with eﬃcacy for tumour
prevention in this group of younger patients. The molecular mechan-
isms underlying the failure of non-postmenopausal women to derive
beneﬁt from zoledronic acid are not yet identiﬁed. Our data suggest
that oestradiol and FSH may be able to inﬂuence the homing to and
survival of DTCs within speciﬁc tumour ‘niches’ either in bone or in
other distant sites. The eﬃcacy of zoledronic acid in aﬀecting survival
of tumour cells may then be diﬀerent according to whether the burden
of DTCs are within bone or not. This remains hypothesis generating
and requires further evidence from both pre-clinical and clinical
research.
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